@article{WU2025, 
author = {Dan WU and Longchen CUI and Fumei XU and Jie WANG and Yanli XU and Qili ZHANG and Jiaojiao LI and Lei ZHAO},
title = {Research progress of the multi-target anti-inflammatory drugs based on the arachidonic acid pathway},
year = {2025},
journal = {Journal of China Pharmaceutical University},
volume = {56},
number = {6},
pages = {782-792},
keywords = {inflammation, arachidonic acid, anti-inflammatory drugs, multitarget-drugs},
url = {https://www.sciopen.com/article/10.11665/j.issn.1000-5048.2024122703},
doi = {10.11665/j.issn.1000-5048.2024122703},
abstract = {Arachidonic acid can be transformed into a variety of metabolites that trigger an inflammatory response through cyclooxygenase, lipoxygenase, cytochrome P450 enzymes, and other metabolic pathways. Moreover, it plays a key role in the occurrence and development of inflammatory diseases. In recent years, multi-target drugs based on the arachidonic acid metabolic pathway have become an important direction of anti-inflammatory drug research. This article summarizes the opportunities and challenges of arachidonic acid metabolic pathways as well as their interference in the development of anti-inflammatory drugs, reviews the research progress of multi-target drug design, synthesis, and anti-inflammatory activity based on the arachidonic acid metabolic pathway, and discusses the difficulties and prospects of multi-target drugs based on metabolic pathways in anti-inflammatory drug development, aiming to provide some reference and inspiration for the study of multi-target anti-inflammatory drugs based on the arachidonic acid metabolic pathway.}
}